STU 022017.032 (NRG-GU002) Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel.
STU 122016.067 (SALV-ENZA) Phase II Randomized Placebo-Controlled Double-Blinded Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy.
STU 022015.058 (IVC Thrombus) Safety Lead-In Phase II Trial of Neo-Adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC.
STU 092017.018 (POTEN-C) Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C): A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) with or without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer. Learn more about the POTEN-C trial.
STU 2019.1065 (STEEL) A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features.
STU 2019.1596 (F-SHARP) A Phase I/II Trial of Focal Salvage High-Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated with Prior Radiotherapy.
STU 2020.0329 (RAVENS) A Phase II Randomized Trial of Radium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers.
STU 022011.213 (ASCLEPIuS) A Multi-Center Study of Androgen Suppression with Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS). A Phase 1/2 Trial in High-Risk or Node-Positive Prostate Cancer.
STU 2021.1091 (NRG-GU010) Parallel Phase III Randomized Trial of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensificiation and Intensification Clinical Trial Evaluation (Guidance).